ZL-1102 (CB001)
Plaque Psoriasis
Phase 2Active (Licensed to Zai Lab)
Key Facts
About Crescendo Biologics
Crescendo Biologics is a private, clinical-stage biotech leveraging its proprietary Humabody® VH platform to develop next-generation, multi-specific immune cell engagers for cancer. Its lead asset, CB307, is a bispecific in Phase 1b for metastatic castration-resistant prostate cancer (mCRPC), with a second program, CB001/ZL-1102 for psoriasis, in Phase 2 via partner Zai Lab. The company is backed by blue-chip investors and has significant discovery and development collaborations with Takeda, BioNTech, and Zai Lab, validating its platform and providing non-dilutive funding.
View full company profileTherapeutic Areas
Other Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Piclidenoson (CF101) | Can Fite Biopharma | Phase III |
| Psoriasis Trial | Clinical Investigation Specialists | Not Specified |
| Encube-001 | Encube Ethicals | Phase 1/2a |
| AX-158 | Artax Biopharma | Phase 2 |
| NG-303 | Nanogen Pharmaceutical Biotechnology | Preclinical |
| Pepticom‑IL17 | Pepticom | Lead Optimization |
| JNJ-2113 | Johnson & Johnson | Phase 3 |
| VTAMA® (tapinarof) | Roivant Sciences | Approved |
| Wynzora | Almirall | Marketed |
| JNJ-81201887 (via Janssen) | OmniAb | Approved |